AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Biologic survival.(ORIGINAL ARTICLES)
ABSTRACT
Background: The results of long-term studies on the efficacy and safety profiles of the biologics for patients with psoriasis are starting to appear in the literature. Not only are the results promising for the biologics as a whole, but the high number of patients remaining in these clinical trials after extended periods of time, or retention, may also reflect additional benefits of these biologics. The aim of this review was to manuscript aims to compare rates of attrition for the various biologic therapies in pivotal clinical trials in order to assess and compare adherence of patients to long-term use of the different biologic agents, also known as ...
- As Patent Expiries Take Their Toll On Small Molecule Blockbuster Drugs Big...
- Press release article from: Business Wire November 27, 2006 700+ words
...small molecule blockbuster drugs Big Pharma are turning to biologic therapies to drive future growth. Alliances and partnerships will...driving the growth of this area Highlights of this title: Biologic therapies will drive the majority of the Big Pharma companies sales...
- Biologic therapies tackle palmoplantar pustulosis.(Skin Disorders)
- Magazine article from: Family Practice News Wendling, Patrice November 1, 2005 700+ words
CHICAGO -- Evidence is mounting that biologic therapies such as alefacept and efallzumab can successfully treat palmoplantar pustular psoriasis. Preliminary data from a pilot study of...
- Biologic therapies may tackle palmoplantar pustular psoriasis.(Dermatology)
- Magazine article from: Internal Medicine News Wendling, Patrice November 1, 2005 700+ words
CHICAGO -- Evidence is mounting that biologic therapies such as alefacept and efalizumab can successfully treat palmoplantar pustular psoriasis. Preliminary data from a pilot study of...
- Newer chemotherapeutic agents, biologic therapies developed for treatment.
- Newspaper article from: Clinical Oncology Week February 24, 2003 700+ words
...researchers in the United States report. "Newer chemotherapeutic agents are being evaluated and innovative biologic therapies are under investigation," wrote S.S. Im and coauthors, University of California, Irvine. The researchers...
- Newer chemotherapeutic agents, biologic therapies developed for...
- Newspaper article from: Cancer Weekly February 25, 2003 700+ words
...researchers in the United States report. "Newer chemotherapeutic agents are being evaluated and innovative biologic therapies are under investigation," wrote S.S. Im and coauthors, University of California, Irvine. The researchers...
- The Systemic Lupus Erythematosus Patient Population in the Seven Major Markets...
- Press release article from: M2 Presswire April 24, 2008 700+ words
...430,000 In 2008 as the Market is Set to Enter Era of Biologic Therapies(C)1994-2008 M2 COMMUNICATIONS LTD RDATE:25042008...Systemic Lupus Erythematosus - Market Set to Enter Era of Biologic Therapies to their offering SLE is a chronic, life-long and potentially...
- Launches of at Least 15 New Biologic Therapies by 2017 Will Expand Treatment...
- Press release article from: PR Newswire May 12, 2008 700+ words
...issues, finds that, in addition to the increasing uptake of currently-marketed biologic drugs, at least 15 new biologic therapies for immune and inflammatory diseases are expected to launch by 2017, compared to fewer than five oral agents...
- Amgen/Wyeth's Enbrel Leads the Market for Biologic Therapies to Treat...
- Press release article from: PR Newswire June 27, 2005 700+ words
...advisory firms for pharmaceutical and health care issues, finds that Amgen/Wyeth's Enbrel leads the market for biologic therapies to treat rheumatoid arthritis and psoriasis. Rheumatologists and dermatologists both prefer Enbrel over all other...